A detailed history of Hancock Whitney Corp transactions in Biogen Inc. stock. As of the latest transaction made, Hancock Whitney Corp holds 2,093 shares of BIIB stock, worth $312,652. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,093
Previous 2,108 0.71%
Holding current value
$312,652
Previous $488,000 17.01%
% of portfolio
0.01%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$189.07 - $236.8 $2,836 - $3,552
-15 Reduced 0.71%
2,093 $405,000
Q2 2024

Aug 13, 2024

SELL
$190.52 - $236.72 $7,430 - $9,232
-39 Reduced 1.82%
2,108 $488,000
Q1 2024

May 16, 2024

BUY
$212.02 - $267.71 $25,442 - $32,125
120 Added 5.92%
2,147 $462,000
Q4 2023

Feb 14, 2024

SELL
$222.59 - $267.94 $31,385 - $37,779
-141 Reduced 6.5%
2,027 $524,000
Q3 2023

Nov 13, 2023

SELL
$253.3 - $285.89 $12,918 - $14,580
-51 Reduced 2.3%
2,168 $557,000
Q2 2023

Nov 13, 2023

SELL
$275.25 - $318.06 $148,635 - $171,752
-540 Reduced 19.57%
2,219 $632,000
Q2 2023

Aug 10, 2023

SELL
$275.25 - $318.06 $148,635 - $171,752
-540 Reduced 19.57%
2,219 $632,000
Q1 2023

Nov 13, 2023

BUY
$256.56 - $292.34 $19,498 - $22,217
76 Added 2.83%
2,759 $767,000
Q1 2023

May 16, 2023

BUY
$256.56 - $292.34 $19,498 - $22,217
76 Added 2.83%
2,759 $767,000
Q4 2022

Nov 13, 2023

BUY
$252.44 - $306.72 $117,132 - $142,318
464 Added 20.91%
2,683 $742,000
Q4 2022

Feb 03, 2023

SELL
$252.44 - $306.72 $55,789 - $67,785
-221 Reduced 7.61%
2,683 $743,000
Q3 2022

Oct 26, 2022

BUY
$194.69 - $268.46 $124,796 - $172,082
641 Added 28.33%
2,904 $775,000
Q2 2022

Aug 08, 2022

BUY
$187.54 - $223.02 $1,875 - $2,230
10 Added 0.44%
2,263 $462,000
Q1 2022

May 12, 2022

SELL
$193.77 - $244.14 $55,418 - $69,824
-286 Reduced 11.26%
2,253 $474,000
Q4 2021

Jan 25, 2022

SELL
$223.92 - $287.77 $86,433 - $111,079
-386 Reduced 13.2%
2,539 $609,000
Q3 2021

Nov 04, 2021

SELL
$282.99 - $369.05 $160,455 - $209,251
-567 Reduced 16.24%
2,925 $828,000
Q2 2021

Aug 09, 2021

SELL
$259.0 - $414.71 $6.54 Million - $10.5 Million
-25,237 Reduced 87.85%
3,492 $1.21 Million
Q1 2021

May 14, 2021

BUY
$242.95 - $284.63 $916,893 - $1.07 Million
3,774 Added 15.12%
28,729 $8.04 Million
Q4 2020

Feb 09, 2021

SELL
$236.26 - $355.63 $1.6 Million - $2.41 Million
-6,768 Reduced 21.33%
24,955 $6.11 Million
Q3 2020

Nov 05, 2020

SELL
$264.77 - $305.71 $340,229 - $392,837
-1,285 Reduced 3.89%
31,723 $9 Million
Q2 2020

Jul 30, 2020

BUY
$258.66 - $342.55 $1.45 Million - $1.92 Million
5,600 Added 20.43%
33,008 $8.83 Million
Q1 2020

May 08, 2020

BUY
$268.85 - $341.04 $3.22 Million - $4.08 Million
11,975 Added 77.59%
27,408 $8.67 Million
Q4 2019

Feb 06, 2020

BUY
$220.06 - $304.07 $13,423 - $18,548
61 Added 0.4%
15,433 $4.58 Million
Q3 2019

Oct 29, 2019

SELL
$217.44 - $243.88 $274,844 - $308,264
-1,264 Reduced 7.6%
15,372 $3.58 Million
Q2 2019

Aug 29, 2019

SELL
$219.29 - $241.72 $216,219 - $238,335
-986 Reduced 5.6%
16,636 $3.89 Million
Q1 2019

May 13, 2019

SELL
$216.71 - $338.96 $28,389 - $44,403
-131 Reduced 0.74%
17,622 $4.17 Million
Q4 2018

Feb 15, 2019

SELL
$278.5 - $352.75 $132,844 - $168,261
-477 Reduced 2.62%
17,753 $5.34 Million
Q3 2018

Nov 14, 2018

BUY
$293.51 - $383.83 $5.35 Million - $7 Million
18,230 New
18,230 $6.44 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Hancock Whitney Corp Portfolio

Follow Hancock Whitney Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hancock Whitney Corp, based on Form 13F filings with the SEC.

News

Stay updated on Hancock Whitney Corp with notifications on news.